## Abstract A murine monoclonal antibody (MAb) to the human insulin receptor (HIR) has been engineered for use as a brain drug delivery system for transport across the human blood–brain barrier (BBB). The HIRMAb was humanized by complementarity determining region (CDR) grafting on the framework reg
Humanization and characterization of the anti-HLA-DR antibody 1D10
✍ Scribed by Sheri A. Kostelny; Brian K. Link; J. Yun Tso; Max Vasquez; Brett H. Jorgensen; Hong Wang; William C. Hall; George J. Weiner
- Publisher
- John Wiley and Sons
- Year
- 2001
- Tongue
- French
- Weight
- 216 KB
- Volume
- 93
- Category
- Article
- ISSN
- 0020-7136
- DOI
- 10.1002/ijc.1366
No coin nor oath required. For personal study only.
✦ Synopsis
1D10 is a previously described antibody that binds to cells from a majority of B-cell malignancies. The current studies were designed to further evaluate the antigen specificity of 1D10 and its potential as an immunotherapeutic agent. Studies with transfectants and immunoprecipitation demonstrated that 1D10 recognizes some, but not all, of the human HLA-DR beta chains. Both normal and malignant B cells can express the 1D10 antigen. A humanized version of 1D10 was produced using CDR grafting. The resulting antibody has an affinity that is similar to that of the parental murine antibody. In addition, the humanized antibody is capable of inducing complement-mediated cytotoxicity, antibody-dependent cell cytotoxicity, and direct apoptosis of 1D10-expressing B cells. Based on these in vitro anti-tumor activities, we conclude humanized 1D10 deserves further evaluation as an immunotherapeutic agent.
📜 SIMILAR VOLUMES
## Abstract ## Objective To examine the association between HLA–DRB1 alleles and the production of anti–cyclic citrullinated peptide (anti‐CCP) and rheumatoid factor (RF) autoantibodies in patients with rheumatoid arthritis (RA). ## Methods We studied 1,723 Caucasian RA patients enrolled in the
Understanding the structural and dynamic determinants of binding free energy in the antigen-antibody bond is of great interest. Much work has focused on selective mutations in order to locate key interaction residues, but this generally results in reduced affinity. The present work instead examines
## Abstract The aim of this study was to determine the inhibition of binding activity of the monoclonal antibody (mAb) D32.10 which recognizes a highly conserved discontinuous antigenic determinant (E1:297–306, E2:480–494, and E2:613–621) expressed on the surface of serum‐derived HCV particles (HCV